No information is available on the clinical use of brodalumab during breastfeeding. Because brodalumab is a large protein molecule with a molecular weight of about 144,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, brodalumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]
关于哺乳期使用布罗达单抗的临床应用尚无可用信息。由于布罗达单抗是一种分子量约为144,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收可能极少。[2]在获得更多数据之前，哺乳期使用布罗达单抗应谨慎，尤其是在哺育新生儿或早产儿期间。产后至少等待2周再恢复治疗可能会减少药物向婴儿的转移。[3]
